Business Description
Travere Therapeutics Inc
NAICS : 325411
SIC : 2834
ISIN : US89422G1076
Share Class Description:
TVTX: Ordinary SharesTotal Employee Number:
497Description
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.79 | |||||
Equity-to-Asset | 0.03 | |||||
Debt-to-Equity | 25.16 | |||||
Debt-to-EBITDA | 106.77 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 3.28 | |||||
Beneish M-Score | -2.37 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 47.4 | |||||
3-Year EPS without NRI Growth Rate | 42.4 | |||||
3-Year FCF Growth Rate | 59.2 | |||||
3-Year Book Growth Rate | 23.7 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 41.29 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 51.13 | |||||
9-Day RSI | 59.5 | |||||
14-Day RSI | 61.7 | |||||
3-1 Month Momentum % | 17.06 | |||||
6-1 Month Momentum % | 87.68 | |||||
12-1 Month Momentum % | 215.88 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.05 | |||||
Quick Ratio | 3.99 | |||||
Cash Ratio | 3.22 | |||||
Days Inventory | 54.02 | |||||
Days Sales Outstanding | 45.65 | |||||
Days Payable | 150.16 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 93.21 | |||||
Operating Margin % | -6.84 | |||||
Net Margin % | -7.35 | |||||
EBITDA Margin % | 0.98 | |||||
FCF Margin % | 2.56 | |||||
OCF Margin % | 15.68 | |||||
ROE % | -63.1 | |||||
ROA % | -7.12 | |||||
ROIC % | -18.02 | |||||
3-Year ROIIC % | -794.75 | |||||
ROC (Joel Greenblatt) % | -354.92 | |||||
ROCE % | -12.57 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 364.63 | |||||
PS Ratio | 10.52 | |||||
PB Ratio | 252.5 | |||||
Price-to-Free-Cash-Flow | 393.11 | |||||
Price-to-Operating-Cash-Flow | 66.05 | |||||
EV-to-EBIT | -109.67 | |||||
EV-to-Forward-EBIT | 942.68 | |||||
EV-to-EBITDA | 1093.11 | |||||
EV-to-Forward-EBITDA | 942.68 | |||||
EV-to-Revenue | 10.68 | |||||
EV-to-Forward-Revenue | 8.99 | |||||
EV-to-FCF | 416.51 | |||||
Price-to-GF-Value | 1.76 | |||||
Price-to-Median-PS-Value | 1.75 | |||||
Earnings Yield (Greenblatt) % | -0.91 | |||||
FCF Yield % | 0.25 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:TVTX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Travere Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 591.331 | ||
| EPS (TTM) ($) | -0.46 | ||
| Beta | 2.3948 | ||
| 3-Year Sharpe Ratio | 0.82 | ||
| 3-Year Sortino Ratio | 1.52 | ||
| Volatility % | 69.8 | ||
| 14-Day RSI | 61.7 | ||
| 14-Day ATR ($) | 2.440167 | ||
| 20-Day SMA ($) | 63.023 | ||
| 12-1 Month Momentum % | 215.88 | ||
| 52-Week Range ($) | 17.27 - 67.85 | ||
| Shares Outstanding (Mil) | 94.26 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Travere Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Travere Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-19 16:30 | In 174 days | ||
| Annual report for 2026 | 2027-02-19 | In 173 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-19 | In 173 days | ||
| Third quarter earnings conference call for 2026 | 2026-10-30 16:30 | In 62 days | ||
| Third quarter earnings results for 2026 | 2026-10-30 | In 61 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-04 16:30 | 54.98 (+0.29%) | ||
| Second quarter earnings results for 2026 | 2026-08-04 | 54.98 (+0.29%) | ||
| Guidance call for 2026 | 2026-06-08 11:20 | 45.81 (-1.48%) | ||
| Guidance call for 2026 | 2026-06-03 08:45 | 42.96 (-2.76%) | ||
| General meeting for 2026 | 2026-05-19 09:00 | 42.89 (+1.30%) |
Show
Entries
Travere Therapeutics Inc Frequently Asked Questions
What is Travere Therapeutics Inc(TVTX)'s stock price today?
The current price of TVTX is $65.65. The 52 week high of TVTX is $67.85 and 52 week low is $17.27.
When is next earnings date of Travere Therapeutics Inc(TVTX)?
The next earnings date of Travere Therapeutics Inc(TVTX) is 2026-10-30 Est..
Does Travere Therapeutics Inc(TVTX) pay dividends? If so, how much?
Travere Therapeutics Inc(TVTX) does not pay dividend.
Guru Commentaries on NAS:TVTX
Abrdn U S Small Cap Equity Fund
Bullish
2026 Q2
What the manager wrote
Travere Therapeutics is a biopharmaceutical company specialising in rare kidney and metabolic disorders. The company’s foundational drug was recently approved for an additional kidney disease, while other promising clinical candidates remain in the pipeline. We believe the combination of these opportunities with strong commercial execution could support growth.
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers